Tag: Solid Tumors

Bayer to Obtain Full Rights on Two Loxo’s Drugs

Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents. Bayer has exercised its option, under a ...

NeoTX in Clinical Collaboration with AstraZeneca

astrazeneca
NeoTX Therapeutics, Ltd announced that it has entered into a clinical collaboration with AstraZeneca Group Plc global biologics research and development arm, MedImmune, to support Phase 1b/2 studies i...

Searching for CAR-T Combinations to Tackle Tumours

Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future. Kisaco Rese...

ADC Starts Clinical Test for Patients with Solid Tumors

ADC Therapeutics, oncology drug specialist started the Phase I clinical testing ADCT-601 on patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed...

4D Pharma and MD Anderson to Assess Solid Tumors Treatment

A strategic collaboration has been formed between 4D pharma and The University of Texas MD Anderson Cancer Center, which is aimed at evaluating 4D’s live biotherapeutic oncology pipeline across a rang...